Waiver Agreements in the Biotechnology Industry
88 Contracts & Agreements
- Adhera Therapeutics, Inc. (3 contracts)
- ADiTx Therapeutics, Inc. (2)
- AGENUS INC (2)
- Aldeyra Therapeutics, Inc. (1)
- Allarity Therapeutics, Inc. (5)
- AMARIN CORP PLC (1)
- ARCA biopharma, Inc. (3)
- ARROWHEAD PHARMACEUTICALS, INC. (1)
- ARYA Sciences Acquisition Corp II (2)
- Axovant Sciences Ltd. (1)
- AzurRx BioPharma, Inc. (2)
- BIO-PATH HOLDINGS INC (1)
- BRAINSTORM CELL THERAPEUTICS INC. (1)
- CATALYST BIOSCIENCES, INC. (6)
- Cellectar Biosciences, Inc. (1)
- Chardan Healthcare Acquisition Corp. (2)
- CLEVELAND BIOLABS INC (1)
- CTI BIOPHARMA CORP (1)
- CytoDyn Inc. (1)
- DYNAVAX TECHNOLOGIES CORP (1)
- Flexion Therapeutics Inc (1)
- FLUOROPHARMA MEDICAL, INC. (1)
- Fortress Biotech, Inc. (1)
- GENEREX BIOTECHNOLOGY CORP (3)
- Greater Cannabis Company, Inc. (1)
- GTX INC (2)
- HedgePath Pharmaceuticals, Inc. (4)
- HEMISPHERX BIOPHARMA INC (2)
- HERON THERAPEUTICS, INC. (2)
- International Stem Cell CORP (3)
- LA JOLLA PHARMACEUTICAL CO (2)
- Leisure Acquisition Corp. (2)
- MARIZYME INC (5)
- MERRIMACK PHARMACEUTICALS INC (1)
- NANOVIRICIDES, INC. (6)
- OPGEN INC (1)
- Orgenesis Inc. (1)
- PIERIS PHARMACEUTICALS, INC. (1)
- REXAHN PHARMACEUTICALS, INC. (1)
- Rich Pharmaceuticals, Inc. (1)
- RITTER PHARMACEUTICALS INC (3)
- SELLAS Life Sciences Group, Inc. (2)
- SPHERIX INC (1)
- TENAX THERAPEUTICS, INC. (1)
- VBI Vaccines Inc (1)
- ZAFGEN, INC. (1)
- Consent and Waiver, dated September 22, 2023, between Qualigen Therapeutics, Inc. and Alpha Capital Anstalt (RITTER PHARMACEUTICALS INC, Filed With SEC on September 28, 2023)
- Limited Waiver between the Company and 3i, LP (Allarity Therapeutics, Inc., Filed With SEC on September 15, 2023)
- Waiver and Consent between Marizyme, Inc. and Waichun Logistics Technology Ltd, dated as of April 12, 2023 (MARIZYME INC, Filed With SEC on August 18, 2023)
- Waiver Agreement between Catalyst Biosciences, Inc. and Ms. Seline Miller, dated January 17, 2023 (CATALYST BIOSCIENCES, INC., Filed With SEC on August 14, 2023)
- Waiver Agreement between Catalyst Biosciences, Inc. and Dr. Grant Blouse, dated January 14, 2023 (CATALYST BIOSCIENCES, INC., Filed With SEC on August 14, 2023)
- Waiver Agreement between Catalyst Biosciences, Inc. and Dr. Nassim Usman, dated January 17, 2023 (CATALYST BIOSCIENCES, INC., Filed With SEC on August 14, 2023)
- Waiver and Second Amendment to Agreement, dated effective as of April 27, 2023, by and between Company and Coalition for Epidemic Preparedness Innovations (DYNAVAX TECHNOLOGIES CORP, Filed With SEC on August 3, 2023)
- Waiver, dated as of April 27, 2023, by and among Cerevel Therapeutics Holdings, Inc. and the investors party thereto (ARYA Sciences Acquisition Corp II, Filed With SEC on August 2, 2023)
- Form of Limited Waiver and Amendment Agreement (Allarity Therapeutics, Inc., Filed With SEC on June 7, 2023)
- 3i, LP - Limited Waiver and Amendment Agreement (Allarity Therapeutics, Inc., Filed With SEC on June 7, 2023)
- Waiver Agreement between Catalyst Biosciences, Inc. and Dr. Nassim Usman, dated January 17, 2023 (CATALYST BIOSCIENCES, INC., Filed With SEC on May 15, 2023)
- Waiver Agreement between Catalyst Biosciences, Inc. and Dr. Grant Blouse, dated January 14, 2023 (CATALYST BIOSCIENCES, INC., Filed With SEC on May 15, 2023)
- Waiver Agreement between Catalyst Biosciences, Inc. and Ms. Seline Miller, dated January 17, 2023 (CATALYST BIOSCIENCES, INC., Filed With SEC on May 15, 2023)
- Limited Waiver Agreement (Allarity Therapeutics, Inc., Filed With SEC on April 25, 2023)
- Limited Waiver Agreement (Allarity Therapeutics, Inc., Filed With SEC on February 28, 2023)
- Waiver and Consent between Marizyme, Inc. and Viner Total Investments Fund, dated January 9, 2023 (MARIZYME INC, Filed With SEC on January 17, 2023)
- Waiver, dated July 22, 2022, between Marizyme, Inc. and Waichun Logistics Technology Limited (MARIZYME INC, Filed With SEC on November 2, 2022)
- Form of Limited Waiver and Consent between Marizyme, Inc. and certain investors (MARIZYME INC, Filed With SEC on November 2, 2022)
- Waiver, dated July 22, 2022, between Marizyme, Inc. and Viner Total Investments Fund (MARIZYME INC, Filed With SEC on November 2, 2022)
- Amendment, Consent and Waiver Agreement, dated as of October 23, 2022, by and between the Company and Ricky Neumann (Orgenesis Inc., Filed With SEC on October 27, 2022)
- Form of First Amendment and Waiver effective as of August 31, 2022 (ADiTx Therapeutics, Inc., Filed With SEC on September 7, 2022)
- Waiver dated June 13, 2022 (TENAX THERAPEUTICS, INC., Filed With SEC on June 16, 2022)
- Waiver and Amendment Letter, dated May 23, 2022 (OPGEN INC, Filed With SEC on May 24, 2022)
- Form of Waiver Agreement (AzurRx BioPharma, Inc., Filed With SEC on May 13, 2022)
- Form of Waiver (CLEVELAND BIOLABS INC, Filed With SEC on March 22, 2022)
- Form of Waiver (AzurRx BioPharma, Inc., Filed With SEC on February 7, 2022)
- Waiver and Amendment between Qualigen Therapeutics, Inc. and Alpha Capital Anstalt, dated November 29, 2021 (RITTER PHARMACEUTICALS INC, Filed With SEC on December 1, 2021)
- Waiver and Defeasance Agreement (ADiTx Therapeutics, Inc., Filed With SEC on August 30, 2021)
- Form of Waiver Agreement, dated as of February 3, 2021, by and between Ocuphire Pharma, Inc. and the Holder(s) (REXAHN PHARMACEUTICALS, INC., Filed With SEC on February 4, 2021)
- Fee Waiver Letter, dated January 31, 2021 (Leisure Acquisition Corp., Filed With SEC on February 2, 2021)
- Waiver, dated January 20, 2021, by and among Cerevel Therapeutics Holdings, Inc. and the investors party thereto (ARYA Sciences Acquisition Corp II, Filed With SEC on January 21, 2021)
- Underwriters Fee Waiver Letter dated November 23, 2020 (Leisure Acquisition Corp., Filed With SEC on November 30, 2020)
- Amendment Number 1 and Waiver Agreement dated December 20, 2018 by and between Helio Vision, Inc. and the Massachusetts Eye and Ear Infirmary (Aldeyra Therapeutics, Inc., Filed With SEC on March 12, 2020)
- Form of Series A Conversion Waiver (NANOVIRICIDES, INC., Filed With SEC on January 8, 2020)
- Form of Series A Conversion Waiver (NANOVIRICIDES, INC., Filed With SEC on January 7, 2020)
- Form of Series A Conversion Waiver (NANOVIRICIDES, INC., Filed With SEC on December 23, 2019)
- Form of Series A Conversion Waiver (NANOVIRICIDES, INC., Filed With SEC on December 17, 2019)
- Form of Series A Conversion Waiver (NANOVIRICIDES, INC., Filed With SEC on November 29, 2019)
- Form of Consent and Waiver with Series B Convertible Preferred Stockholders (RITTER PHARMACEUTICALS INC, Filed With SEC on November 14, 2019)
- Waiver Letter to Voting Agreement (Chardan Healthcare Acquisition Corp., Filed With SEC on November 4, 2019)
